InspireMD’s CEO Steps Down

InspireMD Inc., developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), announced James Barry, Ph.D. is stepping down as president and CEO to pursue other opportunities. The company’s Board of Directors has appointed life sciences industry veteran Marvin Slosman as new CEO, effective January 1, 2020. Slosman will also replace Dr. Barry on the company’s Board of Directors.
 
“Together with my fellow Board members, I would like to welcome Marvin to the InspireMD team and look forward to his leadership and guidance as the company enters its next phase of growth,” said Paul Stuka, InspireMD’s Chairman of the Board of Directors. “We believe Marvin is a proven leader with significant medical technology experience and is the perfect fit to further advance development of CGuard EPS through development in the U.S. while continuing to expand our commercial presence abroad.”
 
“We made many important advancements in the business as well as the ongoing development and commercialization of CGuard during Jim’s tenure. I would like to thank him for his tireless work and many contributions to get us to this point and wish him the best as he begins the next chapter in his professional career,” Stuka concluded.
 
“Throughout my career in medical technology I have had the privilege of contributing to the development and commercialization of many life changing innovations, and I believe CGuard EPS fits well within this category,” said Slosman. “There exists a significant and growing body of clinical evidence demonstrating the superiority of CGuard relative to most other carotid artery disease treatment options, and we believe we have significant opportunity in front of us to greatly expand the availability of this technology to physicians and patients. We will continue to work vigorously toward this goal.”
 
“I would like to thank the Board for the opportunity to serve as CEO, as well as the entire InspireMD team, without whom we could not have achieved important corporate and clinical milestones,” said Dr. Barry. “I believe in the potential of CGuard EPS, which incorporates the company’s proprietary MicroNet technology, to help so many patients globally who suffer from carotid artery disease. We have established a solid foundation from which to drive future growth and success.”
 
Slosman joins InspireMD from Integra LifeSciences, a leading innovator in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. At Integra, he served as Business Consultant overseeing commercial strategy and market development for the Integra’s international business. Before that, he served as president of ITAMAR Medical, a developer of cardiovascular and sleep diagnostic technologies. Prior to ITAMAR, Slosman served as CEO of Ovalum, Ltd., a privately held medical device company focused on arterial conditions. Earlier in his career, Slosman served as CEO of Phormax Medical Inc., senior executive vice president and chief commercial officer at Emerge Interactive in addition to senior commercial leadership positions at Johnson & Johnson, GE Healthcare and Baxter.